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Abstract
Introduction: The associations between leptin, interleukin (IL)-6, and hip radiographic osteoarthritis (OA) have not 
been reported, and their roles in obesity-related hip OA are unclear. The aim of this study was to describe the 
associations between leptin, IL-6, and hip radiographic osteoarthritis (ROA) in older adults.
Methods: A cross-sectional sample of 193 randomly selected subjects (mean age, 63 years; range, 52 to 78 years; 48% 
female subjects) were studied. Hip ROA, including joint-space narrowing (JSN) and osteophytes, was determined by 
anteroposterior radiograph. Serum levels of leptin and interleukin (IL)-6 were measured with radioimmunoassay. Fat 
mass was measured with dual-energy x-ray absorptiometry (DXA). Body mass index (BMI) and waist-to-hip ratio (WHR) 
were calculated.
Results: In multivariable analysis, hip JSN was associated with serum levels of leptin in the whole sample (β = 0.046 per 
μg/L, P = 0.024 for superior; β = 0.068 per μg/L, P = 0.004 for axial compartment) and IL-6 only in females (β = 0.241 per 
pg/ml, P = 0.002 for superior; β = 0.239 per pg/ml, P = 0.001 for axial compartment). The positive associations between 
body-composition measures (BMI, WHR, percentage total fat mass, and percentage trunk fat mass) and hip JSN in 
women became nonsignificant after adjustment for leptin but not for IL-6. No significant associations were found 
between leptin, IL-6, and the presence or severity of osteophytes.
Conclusions: This study suggests that metabolic and inflammatory mechanisms may play a role in the etiology of hip 
OA and that the associations between body composition and hip JSN are mediated by leptin, particularly in women.
Introduction
Osteoarthritis (OA) is a multifactorial disease of the
joints characterized by gradual loss of articular cartilage.
The main risk factors for OA are age [1], female sex [2],
and obesity [1]. Studies of hip OA among predominantly
white populations have estimated prevalence rates of ~5-
7%, which are higher in women [3,4]. Body mass index
(BMI) is strongly associated with prevalence [5] and inci-
dence [6-8] of knee OA. Although inconsistent associa-
tions have been reported between BMI and hip OA [7,9-
11], a systematic review has suggested that BMI is moder-
ately associated with hip OA [12].
Metabolic changes associated with obesity are a possi-
ble causative pathway for OA [13]. Leptin is a 16-kDa
protein encoded by the gene obese (ob) to regulate food
intake and energy expenditure and is correlated with BMI
and female sex [14]. It is secreted mainly by adipocytes
[15], but also by chondrocytes [16,17], and its production
is increased in the cartilage of OA subjects [16]. Leptin
levels in synovial fluid are correlated with BMI [16]; thus,
it is a possible metabolic factor in OA pathogenesis [18],
appearing to mediate obesity- and sex-related knee carti-
lage loss [14]. Leptin is now regarded as a proinflamma-
tory adipocytokine [19] that belongs structurally to the
interleukin (IL)-6 family of cytokines [20,21]. The exact
function of leptin in OA is undetermined, although it is
proposed to have a biphasic effect [22], with low levels
facilitating cartilage synthesis, and excess leptin causing
cartilage inflammation and degeneration [23]. Although
the prevalence of hip OA is lower than that of knee OA,
and some risk factors such as obesity appear not to have
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equal effects on hip and knee OA, effects of leptin on hip
and knee OA may be different. However, as far as we are
aware, the associations between leptin and hip OA have
not been reported.
IL-6 is a cytokine with pro- and antiinflammatory
effects, produced by various types of lymphoid and non-
lymphoid cells as well as chondrocytes and osteoblasts
[24,25]. Like its cousin leptin, IL-6 can be expressed by
adipose tissue [26] and may have mixed roles in OA; IL-6
is able to downregulate catabolic factors involved in carti-
lage degeneration [27,28], but can itself induce inflamma-
tion. Increased IL-6 expression has been observed in
subchondral bone and osteophytes of subjects with knee
OA [25,29]. Circulating levels of both IL-6 and leptin
have been associated with knee O A [14,30]. The func-
tions of IL-6 in hip OA are unclear, and whether it is
involved in any systemic or leptin-mediated process is
unknown. The aim of this study was, therefore, to
describe the relations between radiographic hip OA and
circulating levels of leptin and IL-6 among older adults.
Materials and methods
Subjects
Subjects between ages 50 and 79 years were selected ran-
d o m l y  f r o m  t h e  r o l l  o f  e l e c t o r s  i n  s o u t h e r n  T a s m a n i a
(population, 229,000) with an equal number of men and
women. Institutionalized persons were excluded. This
study was conducted as part of the Tasmanian Older
Adult Cohort Study (TASOAC), an ongoing, prospective,
population-based study in 1,100 subjects aimed at identi-
fying the environmental, genetic, and biochemical factors
associated with the development and progression of
osteoarthritis and osteoporosis (the overall response rate
was 57%). The study was approved by the Southern Tas-
manian Health and Medical Human Research Ethics
Committee, and written informed consent was obtained
from all participants. We selected the first 193 subjects to
perform serum measurements. Self-report of smoking
status and diseases including rheumatoid arthritis,
asthma, cardiovascular disease, and diabetes were
recorded by questionnaire. Hip pain was assessed by
questionnaire and was defined as pain for >24 hours in
the last 12 months or daily pain on >30 days of the last
year.
Anthropometrics
Height was measured to the nearest 0.1 cm (with shoes,
socks, and headgear removed) by using a stadiometer.
Weight was measured to the nearest 0.1 kg (with shoes,
socks, and bulky clothing removed) by using a single pair
of electronic scales (Seca Delta Model 707, Bradford,
MA) that were calibrated by using a known weight at the
beginning of each clinic. Body mass index (BMI; weight
(kg)/height2 (m2)) was also calculated. Waist and hip cir-
cumference were measured and waist-to-hip ratio (WHR;
waist circumference (m)/hip circumference (m)) was cal-
culated.
Total body and trunk fat mass (kg) was measured by a
Hologic dual energy x-ray absorptiometry (DXA) scanner
(Hologic Corp., Waltham, MA, USA). Percentage total
body or trunk fat mass is the ratio of total body or trunk
fat mass divided by total body or trunk mass (i.e., the sum
of fat mass, lean mass, and bone mass). Nontrunk fat
mass (kg) was calculated by subtracting trunk fat mass
from total body fat mass.
Serum measurement
Serum was isolated and refrigerated overnight in plastic
tubes, at which time, aliquots were prepared and stored at
-80°C. The levels of total leptin were measured with
radioimmunoassay (LINCO Research; now part of Milli-
pore, MO, USA) with a specificity of 100%. IL-6 was mea-
sured with a solid-phase, two-site chemiluminescent
enzyme immunometric assay method by use of Immulite
IL-6 (EURO/DPC Llanberis, Gwynedd, UK). Samples
with undetectable concentrations were assigned a value
corresponding to the lower limit of detection of the assay
(sensitivities: 0.5 μg/L for leptin and 2 pg/ml for IL-6).
The coefficients of variation (CVs) in our hands were ~5%
for leptin and 8% for IL-6, as previously published [14,31].
Radiographic measurements
Anteroposterior radiographs of the pelvis with weight
bearing and with both feet in 10 degrees of internal rota-
tion were obtained. Radiographic features of joint-space
narrowing (JSN) (superior and axial) and osteophytes
(superior femoral and superior acetabular) of the left and
right hip were graded on a 4-point scale (range, 0 to 3,
where 0 = no disease and 3 = most-severe disease) by
using the Altman atlas [32], as previously described [33].
Each score was arrived at by consensus between two
readers who simultaneously assessed the radiograph,
with immediate reference to the atlas. The intraobserver
reliability was assessed in 40 subjects, with intraclass cor-
relation coefficients of 0.60 to 0.87 [33].
Data analysis
Student t or Mann-Whitney U tests (where appropriate)
were used to compare means or proportions. Bar graphs
were used to depict median leptin or IL-6 levels for hips
grouped by grade of severity in either compartment.
Because of the low prevalence of grade 3 JSN in this
sample, we combined grades 2 and 3 for analyses. Univar-
iable and multivariable ordered logistic (ordinal) regres-
sions with a partial proportional odds model were used to
examine the associations between JSN and leptin or IL-6
before and after adjustment for age, sex, BMI, ever smok-
ing, and disease status (diabetes, rheumatoid arthritis,
cardiovascular disease, and asthma) in the whole sample,Stannus et al. Arthritis Research & Therapy 2010, 12:R95
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as well as in men or women separately. These associations
were further tested by adjusting for IL-6 for leptin or lep-
tin for IL-6. In this case, ordinal regression provides, for
every unit increase of predictor variable, a ratio of the
odds of JSN severity being greater than or equal to k ver-
sus less than k, where k may be 1 or 2. For ordered vari-
ables, this proportional odds ratio is assumed equal over
all values of k. In the case of a predictor failing to meet
this assumption, a partial proportional odds model pro-
vides a separate odds ratio for each k. β coefficients were
given by the natural logarithms of the odds ratios. The
associations between JSN and body-composition mea-
sures (BMI, WHR, trunk fat ratio, and total fat ratio) were
also investigated by ordinal regression with adjustment
for leptin or IL-6. A P value of < 0.05 (two-tailed) or a 95%
confidence interval not including the null point were con-
sidered statistically significant. All statistical analyses
were performed on Stata V.10.1 for Windows (StataCorp,
College Station, TX, USA), and ordinal regressions were
performed by using Williams' gologit2 function for Stata
[34].
Results
A total of 193 subjects (48% women, aged 52 to 78 years;
mean, 63 years) participated in the present study. Radio-
graphs were unreadable in 12 subjects, and leptin was not
measured in three others because of insufficient serum
samples. Two IL-6 measurements were excluded as outli-
ers (>30 pg/ml). No significant differences were found in
demographic factors between those selected for serum
measurement for this study and the remaining TASOAC
cohort for age, female sex, and BMI (data not shown).
There were 53% subjects having either a JSN or osteo-
phyte score of ≥ 1 in the hip. Characteristics of the sub-
jects are presented (Table 1). No significant differences
were noted between men and women in terms of age,
BMI, prevalent rheumatoid arthritis and diabetes, osteo-
phytes, and IL-6 levels; however, women had significantly
lower lean mass and waist-to-hip ratio, higher percentage
total fat mass and trunk fat mass, and had higher levels of
leptin. Women had a higher prevalence of axial JSN
(grade >0) and asthma, and a lower prevalence of past
smoking, cardiovascular diseases, and hip pain.
A significant positive association between IL-6 and lep-
tin was found after adjustment for age, sex, BMI, smoking
history, and disease status (r = 0.16; P = 0.032), although
this association became nonsignificant when either sex
group was analyzed.
Increasing leptin levels were significantly associated
with severity of hip JSN for either compartment in unad-
justed analyses (superior and axial, both P < 0.001) (Fig-
ure 1a, Table 2). After adjustment for age, sex, BMI,
smoking history, and disease status, serum leptin levels
were significantly positively associated with hip JSN in
both compartments, for separate and combined sex
groups, with the exception of superior JSN in males
(Table 2). To illustrate, for instance, among women, an
increase of 10 μg/L of leptin was associated with an
increase of 10 × 0.043 = 0.43 in superior JSN grade. After
inclusion of IL-6 in the model, the existing associations
were weaker and became of borderline statistical signifi-
cance, except in the axial compartment for women and
both sexes combined.
The interaction term for sex and IL-6 on JSN was sig-
nificant (P  < 0.01), so the analyses of associations
between IL-6 and JSN were performed separately for
women and men. In women, serum IL-6 was significantly
associated with JSN (superior and axial, both P ≤ 0.001)
(Figure 1b, Table 2), and in men, no significant associa-
tions were seen between IL-6 and JSN (Table 2). After
adjustment for the covariates, IL-6 levels were signifi-
cantly positively associated with JSN in either compart-
ment among women (Table 2). These associations
decreased by 16% to 17% but remained significant after
adjustment for leptin.
BMI, WHR, total fat ratio, and trunk-fat ratio were each
significantly associated with leptin (all P < 0.001) after
adjustment for age, sex, height, ever smoked, diabetes,
rheumatoid arthritis, cardiovascular disease, and asthma
(data not shown), whereas only total fat and trunk-fat
ratios were also associated with IL-6 (both P < 0.05). All
four of these anthropometric measures were associated
with superior and/or axial JSN in women (Table 3),
whereas none was associated with JSN in men (Table 4).
For instance, among women, an increase of 5 kg/m2 of
BMI was associated with an increase of 5 × 0.11 = 0.55 in
superior JSN grade, and an increase of 10% in WHR was
associated with an increase of 0.10 × 8.77 = 0.88 in axial
JSN grade. All associations between anthropometric
measures and JSN among women decreased substantially
in magnitude and became statistically nonsignificant
after adjustment for leptin, but remained largely
unchanged after adjustment for IL-6 (Table 3). Nontrunk
fat mass was not associated with hip JSN in either group
(data not shown).
Similar results were obtained for these analyses after
exclusion of subjects with rheumatoid arthritis (data not
shown). In multivariable analysis, hip pain was not signif-
icantly associated with either leptin or IL-6 (data not
shown). We found no significant relations between leptin,
IL-6, and the presence or severity of osteophytes (data
not shown).
Discussion
This cross-sectional study is the first, to our knowledge,
to describe the associations between leptin, IL-6, body
composition, and hip OA in older adults. We found that
serum leptin levels in both sexes and serum IL-6 levels inStannus et al. Arthritis Research & Therapy 2010, 12:R95
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women were positively associated with hip JSN, but not
with osteophytes. The associations were in part depen-
dent on each other, but independent of potential con-
founders, including age, sex, and BMI. Furthermore, we
found that the associations in women between hip JSN
and BMI, fat mass, and WHR were dependent on serum
leptin levels, but not on serum IL-6 levels.
Emerging evidence suggests that leptin may play a role
in knee OA. Chondrocytes possess functional leptin
receptors, and low levels of leptin can promote chondro-
cyte proliferation [35,36] and proteoglycan synthesis [37].
However, overproduction of leptin can increase chondro-
cyte production of IL-1β and matrix metalloproteinases
(MMPs) [23], and in conjunction with IL-1 or interferon
(IFN)-γ, induce nitric oxide synthase (NOS) [38,39],
which accelerates cartilage degradation. Leptin can be
produced within the knee joint [16,40], and concentra-
tions of leptin in synovial fluid have been observed to be
similar to or even higher than those in serum [23,40],
suggesting leptin may have a local influence on the joint.
However, leptin may also contribute to cartilage destruc-
tion through a systemic effect, as suggested by our previ-
ous study, negatively associating serum leptin levels with
knee cartilage volume [14], and as well as studies showing
t h a t  B M I  w a s  a s s o c i a t e d  w i t h  l e p t i n  c o n c e n t r a t i o n s  i n
synovial fluid [16], and that leptin-deficient mice were
less likely to have obesity-induced cartilage degeneration
[41]. The results of this present study suggest that hip OA
may be affected by leptin in a similar manner; however,
its association with the hip appeared stronger than that
we had previously found for the knees, because the signif-
icant associations in the hips were able to be detected by
traditional radiographic assessments, but those in the
knees were detected only by the more-sensitive magnetic
resonance imaging technique [14]. This may also reflect
that radiographic JSN is a more sensitive measure for the
hip than for the knee. Although no equivalent studies
exist with which directly to compare ours, recent clinical
studies in the knee tend to support our results. Regarding
l e v e l s  o f  l e p t i n  i n  k n e e  s y n o v i a l  f l u i d ,  K u  et al. [42]
reported a positive relation between leptin levels and
radiographic severity of OA in a mixed group of 52 sub-
jects, and Gandhi et al. [43] found that the ratio of adi-
ponectin to leptin was negatively associated with knee
Table 1: Characteristics of participants
Both sexes Males Females P
n = 193 n = 100 n = 93
Age, years 62.6 (7.1) 63.3 (7.2) 61.9 (6.9) 0.168a
Body mass index, kg/m2 27.6 (4.4) 27.2 (3.9) 28.0 (4.9) 0.230a
Total lean mass, kg 52.7 (10.8) 60.3 (9.1) 44.6 (5.1) <0.001a
Total fat mass, % 33.7 (7.6) 27.5 (3.8) 40.3 (4.6) <0.001a
Trunk fat mass, % 33.1 (7.6) 28.5 (5.5) 38.0 (6.3) <0.001a
Waist/hip ratio, % 93.4 (8.1) 98.6 (5.4) 87.7 (6.6) <0.001a
Ever smoked, % 51 62 40 0.002
Rheumatoid arthritis, % 11 8 14 0.183
Asthma, % 15 9 21 0.024
Cardiovascular diseases, % 4 7 1 0.039
Diabetes, % 6 3 9 0.093
Hip pain, % 54 63 45 0.013
Superior joint-space 
narrowing, %
41 38 45 0.286
Axial joint-space narrowing, % 30 22 40 0.008
Any joint-space narrowing, % 48 43 52 0.212
Any osteophytes, % 25 28 23 0.419
Leptin, pg/ml 13.0 (11.6) 6.6 (5.6) 19.8 (12.5) <0.001a
IL-6, μg/L 3.5 (1.9) 3.5 (1.9) 3.4 (2.0) 0.672a
Data shown are mean (SD), except for prevalence rates. aSignificance of sex difference by the Student t test, otherwise Mann-Whitney U test. 
IL-6, interleukin-6.Stannus et al. Arthritis Research & Therapy 2010, 12:R95
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pain among a mixed group of 60 subjects. In our results,
it is not surprising that the association between OA and
leptin decreased somewhat in magnitude after adjust-
ment for IL-6, because leptin belongs structurally to the
IL-6 family, and their serum levels were weakly related to
each other in this sample.
Inflammation has been implicated in the pathogenesis
of OA. Although the literature on hip synovitis is scarce,
knee OA has been associated with increased levels of
proinflammatory cytokines, such as IL-6, TNF (tumor
necrosis factor)-α, and IL-1β in synovial fluid [44-46],
and our recent study suggested that serum levels of both
IL-6 and TNF-α were associated with knee cartilage loss
[47]. Data from the Chingford study also reported that
circulating IL-6, but not TNF-α, was associated with OA
progression among women [30]. TNF-α and IL-1α can
induce IL-6 production by synovial fibroblasts in the knee
[48] and promote the catabolic effects of IL-6 on cartilage
[49]; however, in vitro evidence suggests that IL-6 may
reduce cartilage degeneration through inhibition of IL-1
and metalloproteinases [27,28] and promoting produc-
tion of collagen II synthesis by chondrocytes [50], sug-
gesting that IL-6 may also have beneficial effects on
cartilage. Currently, no reports describe associations
between hip OA severity and systemic levels of IL-6. In
this study, we found that serum IL-6 was associated with
hip JSN in women but not in men. This is consistent with
the finding that IL-6 was cross-sectionally associated
with knee ROA collapsed to 3 grades with a large sample
size [30], suggesting that IL-6 also plays a detrimental role
in hip OA in women. The reasons for this sex difference
are unclear; however, it may reflect the influences of sex
hormones in older women. In the absence of estrogen, IL-
6 appears to be an upregulator of bone catabolism, lead-
ing to osteoporosis or fracture or both [31,51], although
the relevance of this to hip OA is not known. Addition-
ally, the lower sample size in the stratified analysis may
have precluded the detection of a more-modest positive
association between IL-6 and hip JSN in men.
Whereas mechanical loading has been suggested as an
intermediary between obesity and OA in the knee and
hips [52], it may not always be a contributing factor, espe-
cially in non-weight-bearing joints such as the hand [7,8].
Consistent with a recent report by Wang et al. [53], we
found that BMI, WHR, body fat, and trunk fat were all
significantly associated with hip JSN in women only; in
contrast, nontrunk fat was not associated with hip JSN.
This suggests that metabolic mechanisms are a possible
alternative or complementary causative pathway between
obesity and OA, at least for women. Indeed, we found
that the positive associations between anthropometric
variables and OA were largely dependent on leptin (but
not IL-6), suggesting that obesity may cause cartilage
damage systemically through production of leptin in adi-
pose tissue in females. The lack of a significant associa-
tion between body-fat measures and hip JSN among men
may be due to modest sample size, and may also reflect a
sex difference in the effect of obesity on hip OA. This is in
contrast with the finding that leptin levels were signifi-
cantly associated with axial JSN in men. However, leptin
can be derived from nonadipose tissue, as discussed ear-
lier, and non-fat-derived leptin can play a role in the etiol-
ogy of hip OA in men. IL-6 was weakly associated with
leptin and also associated with trunk and total fat ratios
in our data, but did not mediate the effect of any of these
fat measures on JSN. Taken together, these results suggest
that leptin, rather than IL-6, is a key adipose factor
involved in hip-cartilage damage. This distinction may be
weaker in knee OA, in which IL-6 and leptin from the
infrapatellar fat pad, with potential paracrine roles, have
been shown to be expressed in greater and lesser propor-
tions, respectively, than in thigh subcutaneous adipose
tissue [54]. Any leptin-mediated effects of obesity may be
complemented by a mechanical loading effect in the
superior compartment, as suggested by the fact that the
consistent associations between obesity measures and
JSN in this compartment remained positive after adjust-
ment for leptin. It is unknown whether mechanical load-
ing can induce the expression of leptin within the joint, as
Figure 1 Associations between hip-joint-space narrowing (JSN). 
(a) Leptin in both sexes. (b) Interleukin (IL)-6 in women only. Statistical 
significance calculated by univariable ordinal regression.
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Table 2: Associations between hip JSN and serum leptin or IL-6 levels
Univariable Multivariablea Multivariableb
β (CI) P β (CI) P β (CI) P
Leptin (grade per μg/L)
superior JSN
Male 0.063 (-0.005 to 0.131) 0.070 0.060 (-0.012 to 0.132) 0.100 0.056 (-0.019 to 0.132) 0.145
Female 0.046 (0.021 to 0.071) <0.001 0.043 (0.004 to 0.083) 0.030 0.038 (-0.001 to 0.078) 0.057
Both sexes 0.047 (0.026 to 0.069) <0.001 0.046 (0.006 to 0.086) 0.024 0.041 (0.000 to 0.082) 0.051
Axial JSN
Male 0.051 (-0.024 to 0.126) 0.182 0.081 (0.007 to 0.154) 0.031 0.077 (-0.002 to 0.155) 0.055
Female 0.041 (0.016 to 0.066) 0.002 0.066 (0.017 to 0.115) 0.008 0.060 (0.011 to 0.109) 0.017
Both sexes 0.052 (0.029 to 0.074) <0.001 0.068 (0.022 to 0.115) 0.004 0.063 (0.014 to 0.112) 0.012
IL-6 (grade per pg/ml)
Superior JSN
Male -0.055 (-0.260 to 0.151) 0.603 -0.066 (-0.268 to 0.136) 0.524 -0.062 (-0.270 to 0.146) 0.556
Female 0.257 (0.115 to 0.400) <0.001 0.241 (0.087 to 0.394) 0.002 0.202 (0.044 to 0.360) 0.012
Both sexes 0.124 (-0.020 to 0.267) 0.092 0.101 (-0.042 to 0.243) 0.166 0.079 (-0.070 to 0.228) 0.297
Axial JSN
Male -0.136 (-0.420 to 0.148) 0.349 -0.138 (-0.409 to 0.134) 0.321 -0.166 (-0.418 to 0.086) 0.197
Female 0.212 (0.085 to 0.338) 0.001 0.239 (0.101 to 0.377) 0.001 0.199 (0.057 to 0.341) 0.006
Both sexes 0.103 (-0.025 to 0.230) 0.116 0.112 (-0.010 to 0.233) 0.071 0.073 (-0.056 to 0.201) 0.267
aAdjusted for age, sex if both sexes, BMI, ever smoked, diabetes, rheumatoid arthritis, heart disease, and asthma. bFurther adjusted for leptin if IL-
6, or IL-6 if leptin. Dependent variable, JSN grade (0-2) in superior or axial compartment. Independent variable, serum level of leptin (μg/L) or IL-
6 (pg/ml). IL-6, interleukin-6; CI, confidence interval; JSN, joint-space narrowing; BMI, body mass index.
Table 3: Associations between body composition and hip JSN in women
Multivariablea Multivariableb Multivariablec
β (CI) P β (CI) P β (CI) P
Superior JSN
BMI (grade per kg/m2) 0.11 (0.03 to 0.19) 0.009 -0.01 (-0.16 to 0.14) 0.874 0.11 (0.03 to 0.19) 0.009
WHR (grade per 100%) 6.86 (-0.36 to 14.07) 0.063 2.69 (-5.05 to 10.42) 0.496 6.04 (-1.05 to 13.14) 0.095
Trunk fat (grade per 100%) 12.61 (5.35 to 19.87) 0.001 7.06 (-3.57 to 17.69) 0.193 11.80 (4.53 to 19.07) 0.001
Total fat (grade per 100%) 13.17 (3.65 to 22.70) 0.007 3.40 (-11.19 to 17.99) 0.648 12.10 (2.60 to 21.60) 0.013
Axial JSN
BMI (grade per kg/m2) 0.08 (-0.01 to 0.16) 0.071 -0.12 (-0.28 to 0.05) 0.174 0.07 (-0.01 to 0.16) 0.084
WHR (grade per 100%) 8.77 (1.39 to 16.14) 0.020 4.88 (-2.88 to 12.64) 0.218 7.58 (0.55 to 14.62) 0.034
Trunk fat (grade per 100%) 8.10 (1.53 to 14.66) 0.016 -0.65 (-10.42 to 9.11) 0.896 6.66 (0.03 to 13.29) 0.049
Total fat (grade per 100%) 7.93 (-0.62 to 16.48) 0.069 -7.18 (-19.50 to 5.14) 0.253 5.64 (-2.79 to 14.08) 0.190
aAdjusted for age, height, ever smoked, diabetes, rheumatoid arthritis, heart disease, and asthma. bFurther adjusted for leptin or cfurther adjusted 
for interleukin-6. Dependent variable, JSN grade (0-2) in superior or axial compartment. Independent variable, BMI, WHR, trunk fat, or total fat (all 
except BMI expressed as percentages between 0 and 100%). IL-6, interleukin-6; CI, confidence interval; JSN, joint-space narrowing; BMI, body 
mass index; WHR, waist-to-hip ratio.Stannus et al. Arthritis Research & Therapy 2010, 12:R95
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has been shown for IL-6 [29,55]; such an effect, if any,
could explain in part the leptin dependence of the associ-
ations between measures of adiposity and hip OA we
report in the current study.
This study has several potential limitations. First, the
modest sample size in this study could impede our dis-
covery of less-strong associations; larger sample size is
required to determine whether the insignificant results
were false negative. This may explain why previous
reports suggested that both leptin and IL-6 are highly
expressed in osteophytes [16,29], yet we were unable to
describe any associations between osteophytes and
serum levels of either. Although our results are in part
corroborated by published knee OA literature, we
emphasize that the restriction of sample size as well as
modest reliability for radiographic measures may influ-
ence the interpretation; replication of these findings
within other groups of subjects is recommended.
Second, a modest response rate (57%) may have intro-
duced selection bias into our sample. However, no signifi-
cant differences were present in age, gender, and BMI
between those who responded and those who did not.
Whereas the sample contained subjects with some dis-
eases, the results were largely unchanged when the analy-
ses were adjusted for disease status or when these
subjects were excluded. We measured serum total leptin
levels rather than free or bound leptin levels, and the lat-
ter may have stronger associations with outcome mea-
sures; however, total leptin and free or bound leptin have
similar patterns in terms of associations with body com-
position and gender [56].
Last, our study is of cross-sectional design, and the
causative relation must be confirmed by future longitudi-
nal studies.
Conclusions
This cross-sectional study suggests that in older adults,
serum levels of leptin in both sexes and IL-6 in women
are positively associated with hip JSN. The associations
between body composition and hip JSN in women are
mediated by leptin. These results that suggest metabolic
and inflammatory mechanisms may play roles in the eti-
ology of hip OA, particularly in females. Replication of
these findings with larger sample size is recommended.
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